Veradermics (MANE) Research & Development (2025 - 2026)

Veradermics' (MANE) quarterly Research & Development came in at $20.9 million in Q1 2026, up 82.8% YoY from $11.4 million in Q1 2025, and up 82.8% on a QoQ basis from $11.4 million in Q1 2025.

Veradermics (MANE) Research & Development (2025 - 2026) Analysis & Trends

Veradermics (MANE) has 2 years of Research & Development data on file, last reported at $20.9 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 993.80 Mn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 1.63 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 1.37 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn - 394.92 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 612.28 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 1,146.05
7 Royalty Pharma 33.72 Bn 35.84 Bn - 97.90 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 413.13 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 210.03 Mn
10 Veradermics 4.70 Bn 4.70 Bn - 18.61 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 18.61 Mn
Mar 31, 2026 20.93 Mn
Mar 31, 2025 11.45 Mn